Translumina Therapeutics LLP

Translumina Therapeutics LLP - healthcare in New Delhi, Delhi, India. Directors, charges & compliance details.
LLPIN AAA-0435 Incorporated 01 December 2009 ROC Delhi HQ New Delhi, Delhi, India
Converted to LLP Limited Liability Partnership healthcare
Data last updated
Revenue · FY 2023
₹375.69 Cr
▲ 39% YoY
EBITDA · FY 2023
₹2.29 Cr
EBITDA margin 0.6%
Contribution obligation
₹1.01 Lakh
As per LLP agreement
Open charges
₹60.95 Cr
Satisfied ₹9.25 Cr
LLP age
17 yrs
Est. 2009
Employees · EPFO
363
Provident fund records
Designated partners
6
As per MCA filings
Active GSTINs
3
of 4 registered

About Translumina Therapeutics LLP

Data last updated:

Translumina Therapeutics LLP was a limited liability partnership (LLP) based in New Delhi, Delhi, India. The LLP has been converted into a company and no longer exists as an LLP. For the latest details, refer to the successor company. It operated in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 01 December 2009.

The LLP was registered with the Registrar of Companies (ROC), Delhi, under LLPIN AAA-0435. Its GSTIN is 05AAGFT2436H1ZB (Uttarakhand). The LLP held 4 GST registrations, of which 3 are active.

The LLP had a total obligation of contribution of ₹1.01 Lakh. It was led by designated partners including Vishal Sharma and Indranil Mukherjee.

Its latest statement of accounts is for the year ended 31 March 2024. The registered office was at Ground Floor Metro Tower Lsc Mor Land New Rajinder Nagar, New Delhi, Delhi, India – 110060.

As per the financials filed for FY 2023, the LLP reported a revenue of ₹375.69 Cr, a growth of 39% compared to the previous year. For the same year it recorded EBITDA of ₹2.29 Cr (EBITDA margin 0.6%). Revenue has grown at a compounded annual rate (CAGR) of 25% over three years and 21% over five years.

The LLP has about 363 employees on its provident fund (EPFO) records.

The LLP is associated with 1 brand: Translumina. As per MCA filings, the LLP has open charges of ₹60.95 Cr and satisfied charges of ₹9.25 Cr on record. Court records list 32 cases involving the LLP, including 13 filed by the LLP and 19 filed against it; 2 cases are pending.

The last known website on record is translumina.com.

Company details

LLPIN AAA-0435
Incorporation Date 01 December 2009
Total Obligation of Contribution ₹1.01 Lakh
ROC Delhi
Listing Status Unlisted
Company Status Converted and Dissolved
Date of Last AGM 31 March 2024
Date of Balance Sheet 31 March 2024

Contact details

Translumina Therapeutics LLP's registered office is in New Delhi, Delhi. Its website is translumina.com. Its e-mail address is in the company report.

  • Email
  • Social Media
  • Apps
  • Registered Address
    Ground Floor Metro Tower Lsc Mor Land New Rajinder Nagar, New Delhi, Delhi, India – 110060
  • Industry
    Healthcare, Medical & Laboratory Equipment

To see the full contact details of Translumina Therapeutics LLP, buy the company report.

Comprehensive company report
Translumina Therapeutics LLP - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Translumina Therapeutics operates one associated brand: Translumina. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of drug-eluting stents and cardiovascular devices. It produces drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories. The company operates advanced manufacturing facilities and is committed to delivering high-quality products. Its focus is on developing and providing innovative cardiovascular intervention technologies. The manufacturing processes adhere to rigorous international standards.translumina.com

Financials of Translumina Therapeutics LLP

FY 2024 filings available

Translumina Therapeutics LLP reported revenue of ₹375.69 Cr (up 39% YoY) for FY 2023.

Revenue · FY 2023
₹375.69 Cr ▲ 39%
EBITDA · FY 2023
₹2.29 Cr margin 0.6%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 39%
3 years · compounded
▲ 25%
5 years · compounded
▲ 21%
EBITDA CAGR growth
1 year
▲ 18%
3 years · compounded
▲ 17%
5 years · compounded
▲ 6%

Revenue has grown at a compounded annual rate (CAGR) of 21% over five years, including 39% growth in the latest year. EBITDA rose 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

Statement of Account and SolvencyFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Income and Expenditure
Turnover
Other Income
Total Income
Purchases and Direct Costs
Personnel Expenses
Administrative Expenses
Interest
Depreciation
Total Expenses
Profit Before Tax
Tax
Profit After Tax
Profit Transferred to Partners
Assets and Liabilities
Partners' Contribution
Reserves and Surplus
Secured Loans
Unsecured Loans
Trade Payables
Other Liabilities and Provisions
Total Liabilities
Fixed Assets
Investments
Loans and Advances
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

Statement of Account and SolvencyFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
Net Profit Margin
Return on Partners' Funds
Return on Assets
Liquidity and Debt
Current Ratio
Debt to Partners' Funds
Interest Coverage
Efficiency and Growth
Asset Turnover
Receivable Days
Turnover Growth
Profit Growth

To see the full financial statements and ratios of Translumina Therapeutics LLP, buy the company report.

Designated partners of Translumina Therapeutics LLP

Translumina Therapeutics has 6 current designated partners and 2 former designated partners. Current designated partners are listed first, with their designation and appointment date.

Designated Partners (as last reported)
NameDesignationAppointment DateTenureStatus
Vishal SharmaDesignated Partner11 Mar 20206 Years 7 MonthsAs last reported
Indranil MukherjeeDesignated Partner15 Mar 20242 Years 7 MonthsAs last reported
Gurmit Singh ChughPartner17 May 20197 Years 5 MonthsAs last reported
Avnish MehraPartner11 Mar 20206 Years 7 MonthsAs last reported
Punita SharmaDesignated Partner01 Dec 200916 Years 10 MonthsAs last reported
Vishal Omprakash GoenkaDesignated Partner15 Mar 20242 Years 7 MonthsAs last reported

Peer comparison

Translumina Therapeutics LLP is compared with the 10 companies closest to it by revenue in the Healthcare industry (Medical and Laboratory Equipment), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Nipro India Corporation Private Limited₹508.66 Cr (FY 2022)9.0%Khandala, Maharashtra, India
Trivitron Healthcare Private Limited₹496.54 Cr (FY 2024)-5.0%Chennai, Tamil Nadu, India
Wipro Ge Medical Device Manufacturing Private Limited₹460.95 Cr (FY 2025)39.0%Bangalore, Karnataka, India
Meril Diagnostics Private Limited₹443.81 Cr (FY 2025)42.0%Vapi, Gujarat, India
Tarsons Products Limited₹408.37 Cr (FY 2025)33.0%Kolkata, West Bengal, India
Translumina Therapeutics LLPthis company₹375.69 Cr (FY 2023)39.0%363New Delhi, Delhi, India
Dynamic Techno Medicals Private Limited₹375.5 Cr (FY 2025)10.0%Ernakulam, Kerala, India
Meril Endo Surgery Private Limited₹367.52 Cr (FY 2025)11.0%Vapi, Gujarat, India
Teleflex Medical Private Limited₹325.62 Cr (FY 2025)18.0%Bengaluru, Karnataka, India
Veiva Scientific India Private Limited₹325.41 Cr (FY 2025)29.0%Bangalore, Karnataka, India
Sensa Core Medical Instrumentation Private Limited₹320.78 Cr (FY 2025)0.0%Pashamylaram, Telangana, India

To see the full peer comparison of Translumina Therapeutics LLP, buy the company report.

Charges & borrowings

Open charges
₹60.95 Cr
Satisfied charges
₹9.25 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹50.55 Cr
Icici Bank Limited₹10.00 Cr
Axis Bank Limited₹0.40 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
18 Nov 2022L-100654416Hdfc Bank Limited₹23 LakhOpen
30 Aug 2022L-100627607Icici Bank Limited₹10 CrOpen
20 Apr 2022L-100629377Hdfc Bank Limited₹16.06 LakhOpen
28 Jan 2022L-100534152Hdfc Bank Limited₹50 CrOpen
27 Nov 2021L-100641135Hdfc Bank Limited₹7.97 LakhOpen

To see the full charge records of Translumina Therapeutics LLP, buy the company report.

Total charge records: 8 View all charges

MSME payment delays

No delayed payments to MSME suppliers are on our record for Translumina Therapeutics LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Translumina Therapeutics LLP has a workforce of 363 employees on its EPFO records as of Feb 08, 2025, across 1 active EPFO establishment.

Employee count
363
Active EPFO establishments
1
Employee growth
-1.63%

GST

Translumina Therapeutics has 4 GST registrations: 3 active and 1 cancelled or inactive.

Total GSTINs
4
Active
3
Cancelled / inactive
1
GSTINStateStatusRegistered on
05AAGFT2436H1ZBUttarakhandActive01 Jul 2017
07AAGFT2436H2Z6DelhiActive01 Jul 2017
08AAGFT2436H1Z5RajasthanActive16 Feb 2022

To see the full GST registrations and return filing status of Translumina Therapeutics LLP, buy the company report.

Recent activity

Translumina Therapeutics LLP has 8 designated partner changes on record since 2009: 6 appointments and 2 cessations. The latest: Indranil Mukherjee was appointed as Designated Partner on 15 Mar 2024.

AGM
Translumina Therapeutics Llp last Annual general meeting of members was held on 31 Mar 2024 as per latest MCA records.
Filing
Translumina Therapeutics Llp has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Appointed
Indranil Mukherjee was appointed as Designated Partner.
Appointed
Vishal Omprakash Goenka was appointed as Designated Partner.
Charges
A charge with Hdfc Bank Limited of Rs. 5,000.00 Lakh registered on 28 Jan 2022 with Charge ID 100534152 was modified on 21 Mar 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 23.00 Lakh with Charge ID 100654416 was registered on 18 Nov 2022.
Charges
A charge registered on 13 Aug 2014 via Charge ID 100104055 with Kotak Mahindra Bank Limited was fully satisfied on 05 Sep 2022.
Charges
A charge with Icici Bank Limited amounted to Rs. 1,000.00 Lakh with Charge ID 100627607 was registered on 30 Aug 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 16.06 Lakh with Charge ID 100629377 was registered on 20 Apr 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 5,000.00 Lakh with Charge ID 100534152 was registered on 28 Jan 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 7.97 Lakh with Charge ID 100641135 was registered on 27 Nov 2021.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 7.97 Lakh with Charge ID 100655400 was registered on 27 Nov 2021.

10 earlier events are in the company report.

Frequently asked questions

Translumina Therapeutics has been converted into a company - the business changed its legal structure from a Limited Liability Partnership to a company. The LLP no longer exists in its previous form. For the latest information, refer to the successor company registered with MCA.

Translumina Therapeutics was a limited liability partnership based in New Delhi, Delhi, India. The LLP worked in medical and laboratory equipment, within the healthcare industry. It was incorporated on 01 December 2009 and is registered under LLPIN AAA-0435. For the latest details, refer to the successor company.

The LLPIN (Limited Liability Partnership Identification Number) of Translumina Therapeutics is AAA-0435. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.

Translumina Therapeutics had 6 designated partners:

Translumina Therapeutics was incorporated on 01 December 2009. It is registered with the Registrar of Companies, Delhi.

Translumina Therapeutics can be reached through the website translumina.com. Its registered office is in New Delhi, Delhi, India.

The registered office of Translumina Therapeutics is at Ground Floor Metro Tower Lsc Mor Land New Rajinder Nagar, New Delhi, Delhi, India – 110060.

The latest financial statements of Translumina Therapeutics on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 31 March 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Translumina Therapeutics is 05AAGFT2436H1ZB, registered in Uttarakhand. The LLP has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 07AAGFT2436H2Z6 (Delhi), 08AAGFT2436H1Z5 (Rajasthan).

Translumina Therapeutics operated in the healthcare industry, in the medical and laboratory equipment segment.

The peers of Translumina Therapeutics by revenue are Nipro India Corporation Private Limited, Trivitron Healthcare Private Limited, Wipro Ge Medical Device Manufacturing Private Limited, Meril Diagnostics Private Limited, Tarsons Products Limited and 5 more, all in the Healthcare industry (Medical and Laboratory Equipment).